(HealthDay News) — Combination nab-paclitaxel and pembrolizumab can produce responses in platinum-refractory or cisplatin-ineligible advanced urothelial cancer, according to research published in The Journal of Urology.
Researchers conducted a single-arm, phase 2 trial of nab-paclitaxel and pembrolizumab in platinum-refractory or cisplatin-ineligible advanced urothelial cancer. Thirty-six response-evaluable patients were enrolled between February 2018 and April 2021.
The median follow-up was 19.7 months. The confirmed overall response rate was 50.0%, which included 3 complete responses and 15 partial responses. The median duration of response was 4.4 months. The median progression-free survival was 6.8 months, and the median overall survival was 18.2 months.
Continue Reading
Grade 3 or higher adverse events occurred in 21 patients and included fatigue (n=6) and anemia (n=4). Immune-mediated adverse events occurred in 10 patients.
“The combination of nab-paclitaxel and pembrolizumab exhibited promising activity in advanced urothelial cancer and warrants further study in this population,” the researchers wrote.
Several researchers disclosed financial ties to biopharmaceutical companies, including Celgene/Bristol Myers Squibb, which manufactures nab-paclitaxel and funded the study.
